Fax: (215) 214-1629
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma†
Version of Record online: 1 DEC 2005
Copyright © 2005 American Cancer Society
Volume 106, Issue 1, pages 51–57, 1 January 2006
How to Cite
Konski, A., Watkins-Bruner, D., Brereton, H., Feigenberg, S. and Hanks, G. (2006), Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer, 106: 51–57. doi: 10.1002/cncr.21575
Presented at the 86th annual meeting of the American Radium Society, Napa, California, May 1–5, 2004.
- Issue online: 23 DEC 2005
- Version of Record online: 1 DEC 2005
- Manuscript Accepted: 28 JUL 2005
- Manuscript Revised: 5 JUL 2005
- Manuscript Received: 5 JAN 2005
- prostate carcinoma;
- androgen deprivation;
- quality-adjusted life years
In Radiation Therapy Oncology Group (RTOG) trial 92-02, after men received neoadjuvant hormone cytoreduction and radiotherapy for locally advanced prostate carcinoma, they were randomized to receive either 2 years of long-term androgen-deprivation (LTAD) or no further treatment (short-term androgen-deprivation [STAD]). The specific objective of the current study was to determine whether LTAD was a cost-effective treatment for patients with locally advanced prostate carcinoma.
The cost-effectiveness of LTAD was tested using a Markov model that was designed using proprietary software. The analysis took a payor's perspective. Unit costs were obtained by estimation using a global Medicare fee schedule. Costs and outcomes were discounted by 3%. Distributions were sampled at random from the treatment utilities, transition probabilities, and costs using a second-order Monte Carlo simulation technique.
The expected mean cost was $32,564 for LTAD compared with $33,039 for STAD after accounting for the additional cost of salvage treatment for men who were treated with STAD. The mean number of quality-adjusted life years (QALYs) for men who received LTAD was 4.13 QALYs compared with a mean of 3.68 QALYs for men who received STAD. The cost-effectiveness acceptability curve analysis showed a 91% probability that LTAD was cost-effective compared with STAD. Although overall survival was similar in the LTAD and STAD groups, the patients who received LTAD experienced gains in QALYs and had lower costs, because LTAD prevented biochemical failure and the necessitating salvage hormone therapy.
The current analysis showed that LTAD was cost-effective for the entire population studied in RTOG trial 92-02. Cancer 2006. © 2005 American Cancer Society.